GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial
for HIV/AIDS Therapeutic Vaccine
Important Milestone in Study of HIV-Infected Individuals Who Started Drug Treatment
During Their First 18 Months of Infection
ATLANTA - December 13, 2011- GeoVax Labs, Inc. (OTCBB:GOVX), an Atlanta-based
biopharmaceutical firm ("the Company") developing vaccines that prevent and fight Human
Immunodeficiency Virus (HIV) infections, announced that the first patient has been inoculated in the
Phase 1/2 clinical trial for the Company's HIV/AIDS therapeutic vaccine. This is the first study using
GeoVax Labs' vaccines for the treatment of persons who are HIV infected.
The protocol for the Phase 1/2 clinical trial will carefully monitor safety while evaluating the ability of
the vaccine to elicit protective immune responses in vaccinated participants. The trial is based on the
achievement of post-vaccine viral control in animal studies conducted in recently infected non-human
primates at the Yerkes National Primate Research Center, affiliated with Emory University.
Robert McNally, Ph.D., President and CEO of GeoVax Labs, stated, "Dosing the first study participant
marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research
Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama,
Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial. These three trial
sites are actively seeking persons who are interested in and fit the criteria for the study."
To be eligible for the study, persons should have started drugs within 18 months of their last HIV
negative test. Persons who have been infected within the past 18 months, but not started drugs, are also
eligible for recruitment into the study. The first participant was enrolled at the AIDS Research
Consortium of Atlanta.
###
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing
HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under
GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness,
and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in
expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope
glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations
and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic
T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1
testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January
2009 and will ultimately involve 300 participants at sites in the United States and South America.
Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals individuals already
infected with HIV. For more information, please visit www.geovax.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters
involve risks and uncertainties that may cause actual results to differ materially, including the following:
changes in economic conditions; general competitive factors; acceptance of the Company's products in
the market; the Company's success in technology and product development; the Company's ability to
execute its business model and strategic plans; and all the risks and related information described from
time to time in the Company's SEC filings, including the financial statements and related information
contained in the Company's SEC Filing. GeoVax assumes no obligation to update the information in this
release.
Contact
The Investor Relations Group:
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.
|
